Italian Institute for Genomic Medicine (IIGM), Istituto Di Ricovero e Cura a Carattere Scientifico (IRCSS) Candiolo, Torino, Italy; Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-IRCCS, Candiolo, Italy.
Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Trends Cancer. 2021 Jun;7(6):557-572. doi: 10.1016/j.trecan.2020.12.012. Epub 2021 Jan 11.
Accumulating preclinical and clinical evidence indicates that high degrees of heterogeneity among malignant cells constitute a considerable obstacle to the success of cancer therapy. This calls for the development of approaches that operate - or enable established treatments to operate - despite such intratumoral heterogeneity (ITH). In this context, oncolytic peptides stand out as promising therapeutic tools based on their ability to drive immunogenic cell death associated with robust anticancer immune responses independently of ITH. We review the main molecular and immunological pathways engaged by oncolytic peptides, and discuss potential approaches to combine these agents with modern immunotherapeutics in support of superior tumor-targeting immunity and efficacy in patients with cancer.
越来越多的临床前和临床证据表明，恶性细胞之间的高度异质性是癌症治疗成功的一个相当大的障碍。这就需要开发能够克服这种肿瘤内异质性（ITH）的方法，或者使已有的治疗方法能够克服这种肿瘤内异质性。在这方面，溶瘤肽作为一种很有前途的治疗工具脱颖而出，其能够驱动免疫原性细胞死亡，与强大的抗肿瘤免疫反应相关，而不受 ITH 的影响。我们综述了溶瘤肽所涉及的主要分子和免疫学途径，并讨论了将这些药物与现代免疫疗法相结合的潜在方法，以支持在癌症患者中具有更优的肿瘤靶向免疫和疗效。
